Skip to main content

Advertisement

Log in

Update multiple endocrine neoplasia type 2

  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Multiple endocrine neoplasia type 2 (MEN2) is a autosomal dominat inherited tumour-syndrome caused by germline activating mutations of the RET proto-oncogene on chromosome 10. It is clinically characterized by the presence of medullary thyroid carcinoma (MTC), bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient. Three distinct clinical forms have been described depending on the phenotype: the classical MEN 2A, MEN 2B, an association of MTC, pheochromocytoma and mucosal neuroma, (FMTC) familial MTC with a low incidence of other endocrinopathies. Each variant of MEN2 results from different RET gene mutation, with a good genotype phenotype correlation. Genetic testing detects nearly 100% of mutation carriers and is considered the standard of care for all first degree relatives of patients with newly diagnosed MTC. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification into four risk levels utilizing the genotype-phenotype correlations. MEN 2 gives a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

MEN:

Multiple endocrine neoplasia

MTC:

Medullary thyroid carcinoma

Ct:

Calcitonin

Pheo:

Pheochromcytoma

HPT:

Primary hyperparathyroidism

FMTC:

Familial medullary thyroid carcinoma

RET gene:

Rearranged during transfection gene

CCH:

C-cell hyperplasia

References

  1. Mulligan LM, Kwok JBJ, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363:458–469

    Article  CAS  PubMed  Google Scholar 

  2. Donis-Keller H, Dou S, Chi D et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genetics 2:851–856

    Article  CAS  Google Scholar 

  3. Raue F, Frank-Raue K, Grauer A (1994) Multiple endocrine neoplasia type 2, clinical features and screening. Endocrin Metab Clin North Am 23:137–156

    CAS  Google Scholar 

  4. Brandi ML, Gagel R, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671

    Article  CAS  PubMed  Google Scholar 

  5. Vasen HF, van der Feltz M, Raue F et al (1992) The natural course of multiple endocrine neoplasia type 2 b. Arch Intern Med 152:1250–1252

    Article  CAS  PubMed  Google Scholar 

  6. Berndt I, Reuter M, Saller B et al (1998) A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774

    Article  CAS  PubMed  Google Scholar 

  7. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612

    Article  PubMed  Google Scholar 

  8. Brauckhoff M, Machens A, Hess S et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044–1051

    Article  PubMed  Google Scholar 

  9. Eng C, Mulligan LM, Smith DP et al (1995) Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123–127

    Article  CAS  Google Scholar 

  10. Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525

    Article  CAS  PubMed  Google Scholar 

  11. LiVolsi VA (1997) C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82:39–41

    Article  CAS  PubMed  Google Scholar 

  12. Grauer A, Raue F, Ziegler R (1998) Clinical usefullness of a new chemoluminescent two-site immunoassy for human calcitonin. Exp Clin Endorcinol Diabetes 106:353–359

    Article  CAS  Google Scholar 

  13. Cohen R, Campos JM, Salaün C et al (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 85:905–918

    Article  Google Scholar 

  14. Mathew CG, Chin KS, Easton DF et al (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527–528

    Article  CAS  PubMed  Google Scholar 

  15. Romei C, Elisei R, Pinchera A et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619–1622

    Article  CAS  PubMed  Google Scholar 

  16. Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687

    Article  CAS  PubMed  Google Scholar 

  17. Mulligan LM, Marsh DJ, Robinson BG et al (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Int Med 238:343–346

    Article  CAS  Google Scholar 

  18. Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575–1579

    Article  CAS  PubMed  Google Scholar 

  19. Frank-Raue K, Höppner W, Frilling A et al (1996) Mutations of the RET proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780–1783

    Article  CAS  PubMed  Google Scholar 

  20. Machens A, Brauckhoff M, Holzhausen HJ et al (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999–4003

    Article  CAS  PubMed  Google Scholar 

  21. Quayle FJ, Fialkowski EA, Benveniste R et al (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800–805

    Article  PubMed  Google Scholar 

  22. Schuffenecker I, Virally-Monod M, Brohet R et al (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487–491

    Article  CAS  PubMed  Google Scholar 

  23. Kouvaraki MA, Shapiro SE, Perrier ND et al (2005) RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531–544

    Article  CAS  PubMed  Google Scholar 

  24. Frank-Raue K, Rondot S, Schulze E et al (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53:273–282

    CAS  PubMed  Google Scholar 

  25. Moers AM, Lansvater RM, Schaap C et al (1996) Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101:635–641

    Article  CAS  PubMed  Google Scholar 

  26. Bolino A, Schuffenecker I, Luo Y et al (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415–2419

    CAS  PubMed  Google Scholar 

  27. Smith DP, Houghton C, Ponder BA (1995) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213–1217

    Article  Google Scholar 

  28. Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803

    Article  CAS  PubMed  Google Scholar 

  29. Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466

    Article  CAS  PubMed  Google Scholar 

  30. Frank-Raue K, Machens A, Scheuba C et al (2008) Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 69:259–263

    Article  CAS  Google Scholar 

  31. Frank-Raue K, Buhr H, Dralle H et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229–236

    Article  CAS  PubMed  Google Scholar 

  32. Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946–956

    Article  PubMed  Google Scholar 

  33. Giraudet AL, Al Ghulzan A, Auperin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246

    Article  CAS  Google Scholar 

  34. Ball DW (2007) Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin N Am 36:823–837

    Article  CAS  Google Scholar 

  35. Sherman SI (2009) Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493–1499

    Article  CAS  PubMed  Google Scholar 

  36. Raue F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck‘s Arch Surg 383:334–336

    Article  CAS  Google Scholar 

  37. Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148

    Article  CAS  PubMed  Google Scholar 

  38. Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathological predictors of survival in 1252 cases. Cancer 107:2134–2142

    Article  PubMed  Google Scholar 

  39. de Groot JW, Plukker JTM, Wolffenbuttel BHR (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729–736

    Article  Google Scholar 

  40. Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132–138

    Article  CAS  PubMed  Google Scholar 

  41. Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. N Engl J Med 353:1105–1113

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Friedhelm Raue.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raue, F., Frank-Raue, K. Update multiple endocrine neoplasia type 2. Familial Cancer 9, 449–457 (2010). https://doi.org/10.1007/s10689-010-9320-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-010-9320-2

Keywords

Navigation